These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2955298)

  • 1. IgA immune complexes and disease: an experimental perspective.
    Rifai A; Imai H; Chen A; Oka D
    Pathol Immunopathol Res; 1986; 5(3-5):278-85. PubMed ID: 2955298
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of nephritogenic IgA immune complexes.
    Rifai A
    Am J Kidney Dis; 1988 Nov; 12(5):402-5. PubMed ID: 3189324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of rat complement by soluble and insoluble immune complexes of rat IgA.
    Rits M; Hiemstra PS; Bazin H; van Es LA; Daha M; Vaerman JP
    Monogr Allergy; 1988; 24():129-33. PubMed ID: 3362139
    [No Abstract]   [Full Text] [Related]  

  • 4. Partial activation of rat complement through the alternative pathway by rat insoluble IgA-immune complexes.
    Rits M; Bazin H; Vaerman JP
    Adv Exp Med Biol; 1987; 216B():1311-5. PubMed ID: 3425431
    [No Abstract]   [Full Text] [Related]  

  • 5. [IgA nephropathy].
    Róg-Marczuk J; Lipski M
    Pol Tyg Lek; 1983 Oct; 38(41):1293-6. PubMed ID: 6231534
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunopathogenesis of IgA nephropathy--new data based on the clinical and experimental studies].
    Krzymański M
    Przegl Lek; 1992; 49(1-2):13-5. PubMed ID: 1454998
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathways of tissue injury initiated by humoral immune mechanisms.
    Emancipator SN; Lamm ME
    Lab Invest; 1986 May; 54(5):475-8. PubMed ID: 2939290
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of complement activation by human IgA immune complexes.
    Imai H; Chen A; Wyatt RJ; Rifai A
    Clin Exp Immunol; 1988 Sep; 73(3):479-83. PubMed ID: 3061690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of polymeric IgA in complement-mediated solubilization of IgG and IgA immune complexes.
    Schena FP; Pastore A; Montinaro V
    Am J Kidney Dis; 1988 Nov; 12(5):433-6. PubMed ID: 3055971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new test for IgA containing immune complexes or aggregated IgA: its application to Berger and Schönlein-Henoch nephritis.
    Coppo R; De Marchi M; Aprato A; Roccatello D; Messina M; Segoloni G; Camussi G; Alloatti S; Giacchino F; Carbonara AO; Vercellone A; Piccoli G
    Proc Eur Dial Transplant Assoc; 1980; 17():667-72. PubMed ID: 7243804
    [No Abstract]   [Full Text] [Related]  

  • 11. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes.
    Pfaffenbach G; Lamm ME; Gigli I
    J Exp Med; 1982 Jan; 155(1):231-47. PubMed ID: 7054357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine.
    Mulligan MS; Warren JS; Smith CW; Anderson DC; Yeh CG; Rudolph AR; Ward PA
    J Immunol; 1992 May; 148(10):3086-92. PubMed ID: 1374449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of IgA-containing circulating immune complexes.
    Hebert LA
    Am J Kidney Dis; 1988 Nov; 12(5):388-92. PubMed ID: 3055964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
    Zhang W; Lachmann PJ
    Immunology; 1994 Jan; 81(1):137-41. PubMed ID: 8132210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.
    Lucisano Valim YM; Lachmann PJ
    Clin Exp Immunol; 1991 Apr; 84(1):1-8. PubMed ID: 1707767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental IgA nephropathy.
    Rifai A; Small PA; Teague PO; Ayoub EM
    J Exp Med; 1979 Nov; 150(5):1161-73. PubMed ID: 159331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA nephropathy: overproduction or decreased clearance of immune complexes?
    Emancipator SN; Lamm ME
    Lab Invest; 1989 Oct; 61(4):365-7. PubMed ID: 2796286
    [No Abstract]   [Full Text] [Related]  

  • 18. The ability of IgA to inhibit complement consumption by complement-fixing antigens and antigen-antibody complexes.
    Russell-Jones GJ; Ey PL; Reynolds BL
    Aust J Exp Biol Med Sci; 1984 Feb; 62 ( Pt 1)():1-10. PubMed ID: 6743139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune abnormalities in IgA nephropathy (Berger's disease).
    Stachura I; Singh G; Whiteside TL
    Clin Immunol Immunopathol; 1981 Sep; 20(3):373-88. PubMed ID: 6210479
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy.
    Jackson S
    Am J Kidney Dis; 1988 Nov; 12(5):425-9. PubMed ID: 3055969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.